Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2017 Annual Meeting Amsterdam, the Netherlands

The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis

Elisabeth Gilis, Céline Mortier, Koen Venken, Karlijn Debusschere, Lars Vereecke and Dirk Elewaut
The Journal of Rheumatology Supplement June 2018, 94 36-39; DOI: https://doi.org/10.3899/jrheum.180135
Elisabeth Gilis
From the Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, University Hospital Ghent; the Vlaams Instituut voor Biotechnologie (VIB) Center for Inflammation Research (IRC), Ghent, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Céline Mortier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koen Venken
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karlijn Debusschere
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Vereecke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Elewaut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Dirk.Elewaut@ugent.be
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Spondyloarthritis (SpA) encompasses a group of diseases characterized by an inflammatory arthritis involving both joints and entheses. However, extraarticular symptoms constitute a large element of the pathology and should not be underestimated. Microscopic gut inflammation is observed in 50% of patients with SpA and has been linked to disease activity, underscoring the effect of gut inflammation in SpA. In this review, we discuss the influence of gut microbiota on SpA pathogenesis. A change in microbiota composition has been linked to the development of various inflammatory arthritides, and dysbiosis is a potential factor in the pathogenesis of multiple inflammatory diseases. In this context, several groups have reported the modulatory effects of gut microbiota-derived metabolites on the effect of immune cells. The gut mucosa is populated by several types of regulatory T cells, but also some specialized unconventional innate-like T cells. These cells are predominantly found at mucosal and epithelial barrier sites, where they serve an essential role in modulating host-microbial interplay. Apart from the close association between the composition of the microbiota and inflammatory diseases, the therapeutic value of dysbiosis needs further investigation, and the identification of a causal inflammatory pathway between gut dysbiosis and musculoskeletal inflammation could revolutionize the therapeutic approach in SpA.

Key Indexing Terms:
  • PSORIATIC ARTHRITIS
  • GRAPPA
  • MICROBIOME
  • JOINTS
  • GUT
  • SPONDYLOARTHRITIS

The Gut: Gateway to Joint Inflammation in Spondyloarthritis

Spondyloarthritis (SpA) consists of a group of chronic inflammatory diseases that primarily affect the musculoskeletal system and share common clinical features, genetic susceptibility, and pathophysiological mechanisms1. These diseases include axial spondyloarthritis, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), some juvenile forms, reactive arthritis, and inflammatory bowel disease (IBD)-associated arthritis. SpA affects up to 1% of Western society2, and its prominent clinical features include inflammatory stiffness, swelling, and/or loss of function of the axial skeleton (spine and sacroiliac joints) and/or peripheral joints, which may lead to irreversible structural and functional impairments and decreased quality of life1. Patients with SpA frequently develop extraarticular manifestations such as acute anterior uveitis, psoriasis, and IBD.

Over the past 3 decades, our group has played a leading role in the examination of gut-joint disease in patients with SpA. We found that about 50% of SpA patients without gastrointestinal symptoms demonstrate microscopic signs of intestinal inflammation. Overall, 6.5% of these patients with SpA evolved to Crohn disease in 5 years’ time, but this fraction reached 20% of patients in the subset with chronic microscopic gut inflammation3,4. Interestingly, the presence of microscopic gut inflammation was also linked to early disease onset, high disease activity, and the presence of bone marrow edema in sacroiliac joints5,6. This finding underscores the potential effect of gut inflammation on the extent of disease in patients with SpA. Conversely, patients with IBD commonly develop joint inflammation with features of SpA1. The mechanism by which gut inflammation affects joint disease has been a longstanding area of research, but is still not well understood. Particularly, it is far from clear how gut microbiota influence SpA pathogenesis.

The human gut harbors a tremendously diverse microbial community, including the microbiota that modulate many physiological processes during homeostasis. The contribution of gut microbiota to the development of gut and joint disease is apparent from multiple experimental animal models, including HLA-B27 transgenic rats7 and SKG mice8. These models mimic gut and joint involvement in human SpA. Interestingly, these models do not develop SpA-like symptoms under germ-free conditions.

The microbiota, however, have been linked to the development of both chronic gut inflammation9 and arthritic pathologies10,11 when its composition is disturbed in animal models.

Dysbiosis, a change in microbial diversity and community composition, has gained much attention as a potential causal or contributing agent to many chronic inflammatory diseases, including IBD and SpA. Important immune- and barrier-modulating functions of the intestinal microbiota are attributed to the fermentation of dietary fibers into short-chain fatty acids (acetate, propionate, and butyrate). In Crohn disease, butyrate-producing bacteria, such as members of the cluster IV and XIVa Clostridia, which are known to steer regulatory T cell (Treg) functionality and to help maintain barrier integrity, are underrepresented9. Beyond butyrate, other metabolites, and antigens associated with Clostridium cluster IV and XIVa have gut barrier-protective effects. There is also evidence that gut microbiota-derived metabolites may modulate immunity by affecting innate-like T cell functions.

Data have shown a reduction of Faecalibacterium prausnitzii, which belongs to the cluster IV Clostridia, in stool samples of patients of SpA12. Moreover, we observed a significant correlation between the abundance of the genus Dialister in ileal and colon biopsies and the Ankylosing Spondylitis Disease Activity Score, a validated measure of disease activity that is widely used in axial SpA13. Other researchers have also found associations between the mucus-degrading Ruminococcus gnavus and Bath Ankylosing Spondylitis Disease Activity Index in AS stool samples14,15.

Collectively, microbial alterations are associated with clinical readouts of inflammation, which suggests the possibility of a connection between dysbiosis and disease status, although it is not firmly established.

Microbial-responsive T Cells in the Intestine: Regulators of Gut and Joint Inflammation?

Genome-wide association studies in both SpA and IBD have revealed polymorphisms in signaling pathways implicated in disease development, such as the interleukin 23 (IL-23) pathway1. This was strikingly shown in the SKG model, which carries a ZAP70 mutation, altering T cell receptor (TCR) signaling that depends on the IL-23/IL-17 pathway for development of gut and joint pathology16,17. These mice only show SpA-like disease (enthesitis and ileitis) when injected with β1,3-glucan, a microbial component16, but not when kept in germ-free conditions8. Further, tumor necrosis factor (TNF), a proinflammatory cytokine, is one of the most important cytokines involved in SpA and IBD pathogenesis, as proven by the success of anti-TNF therapy in both diseases18 and the development of Crohn-like ileitis, sacroiliitis, and enthesitis in a TNF-overexpressing mouse model (TNF∆ARE/+)19. Recently, it was shown that germ-free TNF∆ARE/+ mice do not develop Crohn-like ileitis. TNF∆ARE/+-associated dysbiosis is actively contributing to ileitis development, but its effect on enthesitis and arthritis is currently unknown20. Thus, aberrations in both pathways might result in an altered immune response to mucosal bacteria and their products, leading to disease initiation and progression.

The gut immune system harbors a number of regulatory cells, of which the CD4+CD25+FOXP3+ Tregs are the most studied population. Tregs are very important in maintaining peripheral tolerance and preventing exaggerated immune responses to physiologic environmental entities21. Next to Tregs, the gut mucosa is populated by several highly specialized, unconventional T cells with potent immune-modulatory properties that can also respond to gut microbiota either directly or indirectly. Innate-like T cells, such as invariant natural killer T cells (iNKT), mucosal-associated invariant T (MAIT) cells22, and γ-δ T cells21, are predominantly found at mucosal and epithelial barrier sites where they serve an essential role in modulating host-microbial interplay. These cells can release a broad spectrum of Th1-related cytokines (e.g., interferon-γ and TNF), Th2 (e.g., IL-4 and IL-10), or Th17 (e.g., IL-17 and IL-22) upon TCR activation, but also upon TCR-independent stimulation and act as a “bridge” between innate and adaptive immune responses. iNKT and MAIT cells both express a semi-invariant TCR that shows antigen restriction toward nonpolymorphic MHC-like molecules (CD1d and MR1, respectively) and that respond to microbial-derived products22. iNKT cells recognize bacterial-derived glycolipid molecules, whereas MAIT cells can be activated by vitamin B2 (riboflavin) metabolites, which are endproducts of bacterial and yeast biosynthetic pathways. These innate-like immune cells display plasticity; they can be skewed from an immune-protective role toward a predominant proinflammatory IL-17 profile in response to uncontrolled IL-23 signaling events23. The alteration in cellular phenotype could be mediated either directly or indirectly by chronic inflammation, by an aberrant Treg crosstalk, or by altered microbial-derived signals. There is some evidence from mouse studies that innate-like T cells are functionally skewed with altered features compared to steady state19,24. However, whether these processes also occur in humans and whether there are regional differences according to the site of inflammation remains to be determined.

Is the Intestinal Microbiota a Potential Target for SpA?

Dysbiosis in inflammatory diseases such as SpA is poorly understood. The plasticity of the dysbiosis will determine whether correcting dysbiosis has therapeutic applications. In this context, 2 distinct hypotheses have been proposed to explain the relationship between microbiota and disease association25. The first involves a unidirectional model in which dysbiosis occurs early in life (e.g., influenced by early-life antibiotic exposure, delivery mode, breastfeeding, etc.) with subsequent alterations in the mucosal immune system development. This leads to a permanent alteration in microbiota composition and immune polarization in adult life. Such a scenario has been described in mice lacking lymphotoxin αβ, which affects the formation of gut-associated lymphoid tissue in the neonatal period and leads to the colonization and expansion of segmented filamentous bacteria that ultimately drive IL-17–mediated autoimmunity26. The second model suggests a more reversible balance between microbiota composition, gene susceptibility, and immune activation that is compatible with the therapeutic application of microbiota as a target.

In the context of PsA and SpA, there is evidence for both unidirectional and multidirectional models. For example, breastfeeding was reported to protect against the development of AS27, which could be an indirect link with its effect on microbiota composition. In addition, HLA-B27 may lead to changes in gut microbiota composition28. In psoriasis, a differential relationship exists between microbiota and disease in adult versus neonatal life29. In human PsA, profound changes in microbiota have been described30. Whether similar shifts in microbiota occur in all different forms of SpA is not clear31. Further, whether the gut is the only involved barrier site is equally unclear in view of data on lung microbiota31 and other rheumatic diseases such as rheumatoid arthritis32,33.

The contribution of dysbiosis to inflammatory disease opens perspectives for the development of novel therapies aimed at restoring homeostatic microbial ecological communities. The concept of ecosystem restoration follows the idea that a dysregulated microbiota can be restored by the transfer of specific microbial consortia or even full microbial ecosystems [fecal microbiota transplantation (FMT)] from a healthy donor to a diseased individual. FMT is highly effective in restoring microbial complexity as a treatment for recurrent Clostridium difficile infections in humans34 and for the restoration of rumen function in ruminants35. The success of ecosystem restoration in several diseases may be a key to better understanding the precise effect of microbial changes on SpA disease initiation and progression, especially in analyzing the potential use of microbial supplementation as a therapeutic choice for patients with SpA.

Collectively, the data highlight that much more needs to be understood about the complex interrelation between genetics, environment, and inflammation, including regional and time-dependent effects. Further, the role of microbiota in educating and altering the functionality of local immune cells and its role in the development of SpA needs further research.

Footnotes

  • As part of the supplement series GRAPPA 2017, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.

REFERENCES

  1. 1.↵
    1. Van Praet L,
    2. Jacques P,
    3. Van den Bosch F,
    4. Elewaut D
    . The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol 2012;8:288–95.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Hootman JM,
    2. Helmick CG
    . Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54:226–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mielants H,
    2. Veys EM,
    3. Cuvelier C,
    4. De Vos M,
    5. Goemaere S,
    6. De Clercq L,
    7. et al.
    The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995;22:2279–84.
    OpenUrlPubMed
  4. 4.↵
    1. De Vos M,
    2. Mielants H,
    3. Cuvelier C,
    4. Elewaut A,
    5. Veys E
    . Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696–703.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Van Praet L,
    2. Van den Bosch FE,
    3. Jacques P,
    4. Carron P,
    5. Jans L,
    6. Colman R,
    7. et al.
    Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414–7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Van Praet L,
    2. Jans L,
    3. Carron P,
    4. Jacques P,
    5. Glorieus E,
    6. Colman R,
    7. et al.
    Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis 2014;73:1186–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Taurog JD,
    2. Richardson JA,
    3. Croft JT,
    4. Simmons WA,
    5. Zhou M,
    6. Fernandez-Sueiro JL,
    7. et al.
    The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359–64.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ruutu M,
    2. Thomas G,
    3. Steck R,
    4. Degli-Esposti MA,
    5. Zinkernagel MS,
    6. Alexander K,
    7. et al.
    β-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum 2012;64:2211–22.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Atarashi K,
    2. Tanoue T,
    3. Shima T,
    4. Imaoka A,
    5. Kuwahara T,
    6. Momose Y,
    7. et al.
    Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337–41.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lin P,
    2. Bach M,
    3. Asquith M,
    4. Lee AY,
    5. Akileswaran L,
    6. Stauffer P,
    7. et al.
    HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLoS One 2014;9:e105684.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hoentjen F,
    2. Welling GW,
    3. Harmsen HJ,
    4. Zhang X,
    5. Snart J,
    6. Tannock GW,
    7. et al.
    Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005;11:977–85.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Stoll ML,
    2. Kumar R,
    3. Morrow CD,
    4. Lefkowitz EJ,
    5. Cui X,
    6. Genin A,
    7. et al.
    Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther 2014;16:486.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Tito RY,
    2. Cypers H,
    3. Joossens M,
    4. Varkas G,
    5. Van Praet L,
    6. Glorieus E,
    7. et al.
    Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 2017;69:114–21.
    OpenUrl
  14. 14.↵
    1. Vereecke L,
    2. Elewaut D
    . Spondyloarthropathies: Ruminococcus on the horizon in arthritic disease. Nat Rev Rheumatol 2017;13:574–6.
    OpenUrl
  15. 15.↵
    1. Breban M,
    2. Tap J,
    3. Leboime A,
    4. Said-Nahal R,
    5. Langella P,
    6. Chiocchia G,
    7. et al.
    Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 2017;76:1614–22.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Benham H,
    2. Rehaume LM,
    3. Hasnain SZ,
    4. Velasco J,
    5. Baillet AC,
    6. Ruutu M,
    7. et al.
    Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 2014;66:1755–67.
    OpenUrl
  17. 17.↵
    1. Rehaume LM,
    2. Mondot S,
    3. Aguirre de Carcer D,
    4. Velasco J,
    5. Benham H,
    6. Hasnain SZ,
    7. et al.
    ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. Arthritis Rheumatol 2014;66:2780–92.
    OpenUrl
  18. 18.↵
    1. De Wilde K,
    2. Debusschere K,
    3. Beeckman S,
    4. Jacques P,
    5. Elewaut D
    . Integrating the pathogenesis of spondyloarthritis: gut and joint united? Curr Opin Rheumatol 2015;27:189–96.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Jacques P,
    2. Venken K,
    3. Van Beneden K,
    4. Hammad H,
    5. Seeuws S,
    6. Drennan MB,
    7. et al.
    Invariant natural killer T cells are natural regulators of murine spondylarthritis. Arthritis Rheum 2010;62:988–99.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Schaubeck M,
    2. Clavel T,
    3. Calasan J,
    4. Lagkouvardos I,
    5. Haange SB,
    6. Jehmlich N,
    7. et al.
    Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence. Gut 2016;65:225–37.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Honda K,
    2. Littman DR
    . The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012;30:759–95.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Salio M,
    2. Silk JD,
    3. Jones EY,
    4. Cerundolo V
    . Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol 2014;32:323–66.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Eken A,
    2. Singh AK,
    3. Oukka M
    . Interleukin 23 in Crohn’s disease. Inflamm Bowel Dis 2014;20:587–95.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Kenna TJ,
    2. Davidson SI,
    3. Duan R,
    4. Bradbury LA,
    5. McFarlane J,
    6. Smith M,
    7. et al.
    Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;64:1420–9.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Van de Wiele T,
    2. Van Praet JT,
    3. Marzorati M,
    4. Drennan MB,
    5. Elewaut D
    . How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol 2016;12:398–411.
    OpenUrl
  26. 26.↵
    1. Van Praet JT,
    2. Donovan E,
    3. Vanassche I,
    4. Drennan MB,
    5. Windels F,
    6. Dendooven A,
    7. et al.
    Commensal microbiota influence systemic autoimmune responses. EMBO J 2015;34:466–74.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Montoya J,
    2. Matta NB,
    3. Suchon P,
    4. Guzian MC,
    5. Lambert NC,
    6. Mattei JP,
    7. et al.
    Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study. Ann Rheum Dis 2016;75:879–82.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Asquith M,
    2. Davin S,
    3. Stauffer P,
    4. Michell C,
    5. Janowitz C,
    6. Lin P,
    7. et al.
    Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. Arthritis Rheumatol 2017;69:1984–95.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Zanvit P,
    2. Konkel JE,
    3. Jiao X,
    4. Kasagi S,
    5. Zhang D,
    6. Wu R,
    7. et al.
    Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat Commun 2015;6:8424.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Scher JU,
    2. Ubeda C,
    3. Artacho A,
    4. Attur M,
    5. Isaac S,
    6. Reddy SM,
    7. et al.
    Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128–39.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Manasson J,
    2. Shen N,
    3. Garcia Ferrer HR,
    4. Ubeda C,
    5. Iraheta I,
    6. Heguy A,
    7. et al.
    Gut microbiota perturbations in reactive arthritis and post-infectious spondyloarthritis. Arthritis Rheumatol 2018;70:242–54.
    OpenUrl
  32. 32.↵
    1. Scher JU,
    2. Joshua V,
    3. Artacho A,
    4. Abdollahi-Roodsaz S,
    5. Ockinger J,
    6. Kullberg S,
    7. et al.
    The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 2016;4:60.
    OpenUrl
  33. 33.↵
    1. Thio HB
    . The microbiome in psoriasis and psoriatic arthritis: the skin perspective. J Rheumatol Suppl. 2018 June;94:30–1.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Khoruts A,
    2. Dicksved J,
    3. Jansson JK,
    4. Sadowsky MJ
    . Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010;44:354–60.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. DePeters EJ,
    2. George LW
    . Rumen transfaunation. Immunol Lett 2014;162:69–76.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology Supplement
Vol. 94
1 Jun 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis
Elisabeth Gilis, Céline Mortier, Koen Venken, Karlijn Debusschere, Lars Vereecke, Dirk Elewaut
The Journal of Rheumatology Supplement Jun 2018, 94 36-39; DOI: 10.3899/jrheum.180135

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis
Elisabeth Gilis, Céline Mortier, Koen Venken, Karlijn Debusschere, Lars Vereecke, Dirk Elewaut
The Journal of Rheumatology Supplement Jun 2018, 94 36-39; DOI: 10.3899/jrheum.180135
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • The Gut: Gateway to Joint Inflammation in Spondyloarthritis
    • Microbial-responsive T Cells in the Intestine: Regulators of Gut and Joint Inflammation?
    • Is the Intestinal Microbiota a Potential Target for SpA?
    • Footnotes
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

PSORIATIC ARTHRITIS
GRAPPA
MICROBIOME
JOINTS
GUT
SPONDYLOARTHRITIS

Related Articles

Cited By...

More in this TOC Section

  • The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting
  • Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
  • GRAPPA 2017 Project Report
Show more Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2017 Annual Meeting Amsterdam, the Netherlands

Similar Articles

Keywords

  • psoriatic arthritis
  • GRAPPA
  • MICROBIOME
  • joints
  • GUT
  • spondyloarthritis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire